Active	Status	Sponsor type	Region	Phase	Filter
10 Active 0 Inactive 10 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

10 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Zhao, Bing
LEONARDA-1, NCT05054751: GB491 Combined With Fulvestrant for HR+ HER2- Locally Advanced or Metastatic Breast Cancer	Completed	3	275	RoW	GB491+ Fulvestrant, test drug + Fulvestrant, Placebo+Fulvestrant, placebo control + Fulvestrant	Genor Biopharma Co., Ltd.	Locally Advanced or Metastatic Breast Cancer	12/22	03/24
NCT05433480: A Study of BPI-16350 in Combination With Fulvestrant in Patients With HR+ and HER2- Locally Advanced, Recurrent or Metastatic Breast Cancer	Active, not recruiting	3	274	RoW	BPI-16350, placebo, Fulvestrant	Betta Pharmaceuticals Co., Ltd.	Breast Cancer	12/23	07/25
LEONARDA-2, NCT05851014: A Study of GB491 in Combination With Letrozole in Patients With HR Positive and HER2 Negative Advanced Breast Cancer	Recruiting	3	350	RoW	GB491 combined with Letrozole, Placebo combined with Letrozole	Genor Biopharma Co., Ltd.	Breast Cancer	01/26	01/27
EMBER-4, NCT05514054: A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer	Recruiting	3	6000	Europe, Canada, Japan, US, RoW	Imlunestrant, LY3484356, Tamoxifen, Anastrozole, Letrozole, Exemestane	Eli Lilly and Company	Breast Neoplasms	10/27	03/32
TQB3616-II-01, NCT04773418: A Study of TQB3616 Capsules Combined With Fulvestrant Injection in Subjects With Advanced Breast Cancer	Recruiting	2	120	RoW	TQB3616 capsules, Fulvestrant injection	Chia Tai Tianqing Pharmaceutical Group Co., Ltd.	HR-positive, HER2-negative Advanced Breast Cancer	01/23	01/23
TQB3616-II-01, NCT04796623: A Study of TQB3616 Capsules Combined With Fulvestrant Injection in Subjects With Advanced Breast Cancer	Recruiting	2	120	RoW	TQB3616 capsules, Fulvestrant injection	Chia Tai Tianqing Pharmaceutical Group Co., Ltd.	HR-positive, HER2-negative Advanced Breast Cancer	01/23	01/23
NCT04927481: A Study of Mitoxantrone Hydrochloride Liposome Injection in Patients With Advanced HER2 Negative Breast Cancer	Terminated	2	28	RoW	Mitoxantrone Hydrochloride Liposome Injection	CSPC ZhongQi Pharmaceutical Technology Co., Ltd.	Breast Cancer	01/23	01/23
NCT06569524: Efficacy and Safety of Recombinant Human FGF21-Fc Fusion Protein for Injection (TQA2225/AP025) in Adult Subjects With Non-alcoholic Steatohepatitis (NASH)	Recruiting	2	120	RoW	TQA2225/AP025 or TQA2225/AP025 Placebo 25mg, TQA2225/AP025 or TQA2225/AP025 Placebo 50mg	Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.	Non-alcoholic Steatohepatitis	12/26	12/27
TQB2102-II-02, NCT06452706: The Clinical Trial of TQB2102 for Injection Against Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer	Recruiting	2	42	RoW	TQB2102 for injection	Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.	Breast Cancer	06/26	06/28
TQB2102-Ib-01, NCT06115902: A Study of TQB2102 for Injection in Patients With Recurrent/Metastatic Breast Cancer	Recruiting	1	150	RoW	TQB2102 for injection	Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.	Breast Cancer	12/25	12/26